{"id":"https://openalex.org/W2619782245","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.e19137","title":"Prescribing preferences (PPrefs) of US-based medical oncologists (MOs) for 1st salvage therapy (Tx) after response to 1st-line crizotinib (CRZ) in patients with anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC).","display_name":"Prescribing preferences (PPrefs) of US-based medical oncologists (MOs) for 1st salvage therapy (Tx) after response to 1st-line crizotinib (CRZ) in patients with anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC).","publication_year":2015,"publication_date":"2015-05-20","ids":{"openalex":"https://openalex.org/W2619782245","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.e19137","mag":"2619782245"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2015.33.15_suppl.e19137","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.e19137","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2015.33.15_suppl.e19137","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078629724","display_name":"Mark A. Socinski","orcid":"https://orcid.org/0000-0003-2915-9325","observed_orcids":["https://orcid.org/0000-0003-2915-9325","https://orcid.org/0000-0002-8213-0137"]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark A. Socinski","raw_affiliation_strings":["University of Pittsburgh, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh, Pittsburgh, PA","institution_ids":["https://openalex.org/I170201317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043909412","display_name":"Arden Buettner","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Arden Buettner","raw_affiliation_strings":["Xcenda, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Xcenda, Tampa, FL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028935523","display_name":"Maria L. Lankford","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Maria L. Lankford","raw_affiliation_strings":["Xcenda, Palm Harbor, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Xcenda, Palm Harbor, FL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039907613","display_name":"Doug B. Neely","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Doug B. Neely","raw_affiliation_strings":["Xcenda, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Xcenda, Tampa, FL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028615214","display_name":"Brynn Tiscione","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Brynn Tiscione","raw_affiliation_strings":["Xcenda, Palm Harbor, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Xcenda, Palm Harbor, FL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035911953","display_name":"Joanne P. Willey","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joanne P. Willey","raw_affiliation_strings":["Xcenda, Covington, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Xcenda, Covington, GA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111684895","display_name":"Mark R. Green","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark R. Green","raw_affiliation_strings":["Xcenda, Palm Harbor, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Xcenda, Palm Harbor, FL","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"33","issue":"15_suppl","first_page":"e19137","last_page":"e19137"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/crizotinib","display_name":"crizotinib","score":0.9800000190734863},{"id":"https://openalex.org/keywords/anaplastic-lymphoma-kinase","display_name":"anaplastic lymphoma kinase","score":0.8709999918937683},{"id":"https://openalex.org/keywords/alk-positive-non-small-cell-lung-cancer","display_name":"ALK-positive non-small cell lung cancer","score":0.9950000047683716},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.7850000262260437},{"id":"https://openalex.org/keywords/salvage-therapy","display_name":"salvage therapy","score":0.902999997138977},{"id":"https://openalex.org/keywords/prescribing-preferences","display_name":"prescribing preferences","score":0.9319999814033508},{"id":"https://openalex.org/keywords/medical-oncologists","display_name":"medical oncologists","score":0.871999979019165},{"id":"https://openalex.org/keywords/ceritinib","display_name":"ceritinib","score":0.9919999837875366},{"id":"https://openalex.org/keywords/pemetrexed","display_name":"pemetrexed","score":0.8650000095367432},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.9929999709129333},{"id":"https://openalex.org/keywords/failure-patterns","display_name":"failure patterns","score":0.6840000152587891},{"id":"https://openalex.org/keywords/fda-approval","display_name":"FDA approval","score":0.6449999809265137},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.5270000100135803},{"id":"https://openalex.org/keywords/market-research","display_name":"market analysis","score":0.4099999964237213}],"concepts":[{"id":"https://openalex.org/C2779422266","wikidata":"https://www.wikidata.org/wiki/Q5186964","display_name":"Crizotinib","level":4,"score":0.9655353426933289},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.884811520576477},{"id":"https://openalex.org/C2779750558","wikidata":"https://www.wikidata.org/wiki/Q21011233","display_name":"Ceritinib","level":5,"score":0.7118978500366211},{"id":"https://openalex.org/C117643217","wikidata":"https://www.wikidata.org/wiki/Q17824987","display_name":"Anaplastic lymphoma kinase","level":4,"score":0.6990991830825806},{"id":"https://openalex.org/C2778347629","wikidata":"https://www.wikidata.org/wiki/Q4652380","display_name":"ALK inhibitor","level":5,"score":0.5732424259185791},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.5615059733390808},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5512767434120178},{"id":"https://openalex.org/C2777240266","wikidata":"https://www.wikidata.org/wiki/Q415220","display_name":"Pemetrexed","level":4,"score":0.5218009948730469},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5215825438499451},{"id":"https://openalex.org/C2780775027","wikidata":"https://www.wikidata.org/wiki/Q17141389","display_name":"Salvage therapy","level":3,"score":0.43119820952415466},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.22462332248687744},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.17776691913604736},{"id":"https://openalex.org/C2776232967","wikidata":"https://www.wikidata.org/wiki/Q6743514","display_name":"Malignant pleural effusion","level":3,"score":0.0},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2015.33.15_suppl.e19137","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.e19137","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2015.33.15_suppl.e19137","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8560000061988831}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2998884390","https://openalex.org/W2318660237","https://openalex.org/W2782109468","https://openalex.org/W2562488255","https://openalex.org/W2353795686","https://openalex.org/W2892036113","https://openalex.org/W2460951028","https://openalex.org/W4255779253","https://openalex.org/W2898536080","https://openalex.org/W2892243705"],"abstract_inverted_index":{"e19137":[0],"Background:":[1],"Crizotinib":[2],"is":[3,18],"standard":[4],"1st":[5,244],"line":[6,12,52,245],"Tx":[7,13,68,172,179,246],"for":[8,124,181,188,219,249],"ALK-positive":[9,33],"NSCLC.":[10,152,254],"2nd":[11,51],"after":[14,166,243],"progression":[15,229],"on":[16,62,157,178],"CRZ":[17,212,248,305,317],"less":[19,213],"well":[20,173],"defined.":[21],"Shaw,":[22],"et":[23],"al":[24],"(N":[25],"Engl":[26],"J":[27],"Med":[28],"2013;":[29],"368:2385-2394)":[30],"showed":[31,149],"that":[32,235],"NSCLC":[34],"patients":[35,250],"have":[36],"higher":[37],"response":[38],"rates":[39],"and":[40,105,114,122,174,258,286,293,315],"improved":[41],"PFS":[42],"with":[43,204,247,251],"pemetrexed":[44],"(PEM)":[45],"relative":[46],"to":[47,55,366],"docetaxel":[48],"in":[49,110,191],"the":[50,56,146,155,171,216,224],"setting.":[53],"Prior":[54],"FDA":[57,195,296],"approval":[58,260],"of":[59,78,128,141,145,200,226,228,237,261,265,277],"ceritinib":[60],"(CER)":[61],"April":[63],"29,":[64],"2014,":[65],"no":[66],"salvage":[67],"specifically":[69],"targeting":[70],"ALK":[71,150,252,349],"was":[72,120],"available.":[73],"Methods:":[74],"Prescribing":[75],"preferences":[76,242],"(PPrefs)":[77],"364":[79,272],"U.S.-based":[80],"medical":[81],"oncologists":[82],"(MOs)":[83],"were":[84,98,131],"studied":[85],"using":[86,100],"a":[87,138,162,208],"validated,":[88],"proprietary,":[89],"live,":[90],"case-based":[91],"market":[92],"research":[93],"tool":[94],"(Challenging":[95],"Cases).":[96],"Data":[97],"acquired":[99],"blinded,":[101],"audience-response":[102],"iPad":[103],"technology":[104],"acquisition":[106],"events":[107],"took":[108],"place":[109],"April,":[111],"May,":[112],"August":[113],"November":[115],"2014.":[116],"A":[117,197],"core":[118],"case":[119],"constructed":[121],"PPrefs":[123,187,218,255],"three":[125],"different":[126],"patterns":[127,236],"treatment":[129],"failure":[130,238],"assessed.":[132],"Core":[133],"case:":[134],"57-year-old":[135],"man":[136],"has":[137,176],"new":[139],"diagnosis":[140],"stage":[142],"IV":[143],"adenocarcinoma":[144],"lung.":[147],"Pathology":[148],"positive":[151,253],"You":[153],"began":[154],"patient":[156],"daily":[158],"CRZ.":[159],"He":[160,169],"had":[161],"clear":[163],"RECIST":[164],"PR":[165],"8":[167,182],"weeks.":[168],"tolerated":[170],"he":[175],"been":[177],"continuously":[180],"months.":[183],"Results:":[184],"See":[185],"table.":[186],"CER":[189,220,262,340],"increased":[190,221],"each":[192],"scenario":[193],"post":[194],"approval.":[196],"single":[198],"site":[199,314],"failure,":[201],"managed":[202],"definitively":[203],"local":[205],"Tx,":[206],"triggers":[207],"move":[209],"away":[210],"from":[211],"than":[214],"half":[215],"time.":[217],"most":[222],"as":[223],"number":[225],"sites":[227],"increased.":[230],"Conclusions:":[231],"These":[232],"data":[233],"indicate":[234],"strongly":[239],"influence":[240],"prescribing":[241],"by":[256,263],"pre-":[257],"post-FDA":[259],"pattern":[264],"failure.*":[266],"N":[267,270,273],"=":[268,271,274],"360":[269,275],"Pattern":[276],"Failure":[278],"Single":[279],"brain":[280],"met":[281,284,288],"(resected)":[282,285],"Brain":[283],"liver":[287,313],"Brain,":[289],"bone,":[290],"lung,":[291],"intrathoracic,":[292],"adrenal":[294],"mets":[295],"Approval":[297],"Pre":[298,300,302],"Post":[299,301,303],"Continue":[304],"78%":[306],"58%":[307],"14%":[308],"7%":[309,326,355],"NO":[310,311,318,319,322,323,357],"Radiate":[312],"continue":[316],"36%":[320],"24%":[321],"PEM-based":[324],"CT":[325,333],"10%":[327,341],"12%":[328,329],"37%":[330],"28%":[331],"Other":[332],"1%":[334],"4%":[335,339,354],"6%":[336],"2%":[337,353],"11%":[338],"26%":[342],"30%":[343],"51%":[344],"44%":[345],"61%":[346],"Other-including":[347],"other":[348],"inhibitors":[350],"3%":[351,352],"5%":[356],"-":[358],"not":[359,362],"offered;":[360],"*May":[361],"equal":[363],"100%":[364],"due":[365],"rounding":[367]},"counts_by_year":[],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2017-06-05T00:00:00"}